A Phase III Randomized Trial For Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail Or In A Subset of “Intermediate Fit” Comparing Upfront Three-Drug Induction Regimens Followed by Double- or Single-Agent Maintenance

The purpose of this study is to compare the usual treatment plan to using a different combination of drugs. Researchers will test a different combination of drugs called DRd. DRd combines 3 drugs for treatment: daratumumab and hyaluronidase, lenalidomide, and dexamethasone. Using the study treatment instead of the usual treatment could reduce or control the cancer better. The study treatment may also cause side effects which the doctors will be watching for. This study will help the study doctors learn which combination of drugs is better among the usual treatments for multiple myeloma patients who are not receiving stem cell transplant. To decide which combination is better, the study doctors will be looking to see if the study approach increases the life of patients compared to the usual approach. All drugs in this study are FDA-approved to treat multiple myeloma.

Are you Eligible? (Inclusion Criteria)

• Are you 18 years of age or older? Have you been diagnosed with multiple myeloma and have not yet received any courses of treatment for it? Are you able to make regularly scheduled visits to the clinic for treatment and assessments?